Open for inclusion

A phase I, open-label, multi-arm, multi-centre, multi-dose, dose escalation study of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumours

Cancer type: Multiple diagnosis

Phase: I

Principal Investigator: Omenaas Ernst

Country: NO

Keywords: Norway, Bergen, Lytix, multiple diagnosis, LTX-315,Ipilimumab, prembolizumab

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT01986426?term=C12-315-03&rank=1